BR112018008601A2 - composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer - Google Patents

composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer

Info

Publication number
BR112018008601A2
BR112018008601A2 BR112018008601A BR112018008601A BR112018008601A2 BR 112018008601 A2 BR112018008601 A2 BR 112018008601A2 BR 112018008601 A BR112018008601 A BR 112018008601A BR 112018008601 A BR112018008601 A BR 112018008601A BR 112018008601 A2 BR112018008601 A2 BR 112018008601A2
Authority
BR
Brazil
Prior art keywords
cannabidiol
cancer
compositions
treatment
therapeutic agents
Prior art date
Application number
BR112018008601A
Other languages
English (en)
Inventor
Juknat Geralnik Adela
Nathan Ilana
Narasaiah Uppalapati Lakshmi
Vogel Zvi
Original Assignee
Jay Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jay Pharma Inc filed Critical Jay Pharma Inc
Publication of BR112018008601A2 publication Critical patent/BR112018008601A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

a invenção proporciona combinações sinérgicas de canabidiol (cbd) e um segundo agente terapêutico, tal como um ou mais inibidores de cheh/aebs, uma naftoquinona ou um derivado da mesma, ou qualquer combinação dos mesmos, eficaz para o tratamento de câncer. composições contendo os mesmos e métodos de uso dos mesmos são descritos.
BR112018008601A 2015-10-27 2016-10-27 composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer BR112018008601A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562246780P 2015-10-27 2015-10-27
PCT/IL2016/051166 WO2017072773A1 (en) 2015-10-27 2016-10-27 Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112018008601A2 true BR112018008601A2 (pt) 2018-10-30

Family

ID=57406292

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008601A BR112018008601A2 (pt) 2015-10-27 2016-10-27 composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer

Country Status (10)

Country Link
US (1) US11090275B2 (pt)
EP (1) EP3368024B1 (pt)
JP (1) JP7078538B2 (pt)
KR (1) KR20180102053A (pt)
CN (1) CN109310648B (pt)
AU (1) AU2016347662B2 (pt)
BR (1) BR112018008601A2 (pt)
CA (2) CA3187317A1 (pt)
IL (1) IL258854A (pt)
WO (1) WO2017072773A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020161083A1 (en) * 2019-02-04 2020-08-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating blood-brain barrier
US20230090094A1 (en) * 2019-07-02 2023-03-23 Ellevet Sciences Hemp extract for treatment of pain, cancer and epilepsy in animals
EP3826630B1 (en) * 2019-07-21 2022-06-29 SCF Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides and use thereof
WO2021203206A1 (en) * 2020-04-09 2021-10-14 Laviolette Steven Robert Combination of cannabidiol and a ppar agonist
CN111773390B (zh) * 2020-07-01 2021-08-20 南京大学 一种药物在制备治疗脑转移瘤及其相关疾病的药品中的应用
CN113368085A (zh) * 2021-06-05 2021-09-10 昆明医科大学第一附属医院 ***二酚在调节肿瘤微生态治疗乳腺癌药物研制中的应用
CN113384563A (zh) * 2021-06-16 2021-09-14 冯敏 ***二酚在制备治疗非霍奇金淋巴瘤的药物中的应用
WO2023076928A1 (en) 2021-10-26 2023-05-04 Ecofibre Limited Methods of treating ovarian cancer with hemp extract
WO2024003373A1 (en) * 2022-06-30 2024-01-04 Univerza V Mariboru Cannabinoid compositions against cancer, their identification and personalization of cannabis-based cancer therapy
US20240009211A1 (en) * 2022-07-05 2024-01-11 Neocannbio Co., Ltd. Pharmaceutical composition for treatment of lung cancer comprising cannabidiol and anticancer agent as active ingredients, and use thereof
KR20240036953A (ko) * 2022-09-14 2024-03-21 주식회사 네오켄바이오 칸나비디올 및 항암제를 유효성분으로 포함하는 간암 치료용 약학 조성물 및 이의 용도

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
WO1992011035A1 (en) * 1990-12-17 1992-07-09 University Of Manitoba Improved treatment method for cancer
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6380253B1 (en) * 2000-01-05 2002-04-30 Efa Sciences Llc Method of stabilizing and potentiating the action of anti-angiogenic substances
US20020040011A1 (en) * 2000-06-01 2002-04-04 Brown Dennis M. Naphthoquinone compositions and uses thereof
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US9084771B2 (en) * 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2475183B (en) * 2008-06-04 2011-11-23 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators
FR2947340B1 (fr) * 2009-06-25 2011-08-12 Affichem Detection de l'etat oncogene de cellules humaines ou de mammiferes par presence d'un marqueur et evaluation de l'activite d'un medicament par dosage dudit marqueur
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
GB2527590A (en) * 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer

Also Published As

Publication number Publication date
IL258854A (en) 2018-06-28
CA3002767C (en) 2023-03-14
AU2016347662B2 (en) 2021-12-02
EP3368024A1 (en) 2018-09-05
KR20180102053A (ko) 2018-09-14
US20180311182A1 (en) 2018-11-01
WO2017072773A1 (en) 2017-05-04
JP7078538B2 (ja) 2022-05-31
CA3187317A1 (en) 2017-05-04
AU2016347662A1 (en) 2018-05-10
CN109310648A (zh) 2019-02-05
EP3368024B1 (en) 2023-09-20
CA3002767A1 (en) 2017-05-04
JP2018536706A (ja) 2018-12-13
US11090275B2 (en) 2021-08-17
CN109310648B (zh) 2022-06-03

Similar Documents

Publication Publication Date Title
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112017023904A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
BR112017006299A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
CO2018009563A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
CY1122968T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο
MX2017015923A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).
BR112017026104A2 (pt) novos usos de derivados de aril-quinolina como inibidores de mimetismo vasculogênico
BR112018002530A2 (pt) combinações e usos e tratamentos destas
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
BR112017021559A2 (pt) composições e métodos para tratamento sinérgico do glicocálice

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]